CJC-1295: Complete 2026 Guide to Dosing, Benefits, and the Ipamorelin Stack

If you've spent any time researching growth hormone optimization, you've almost certainly come across CJC-1295. It's one of the most widely used peptides in the longevity, body composition, and performance space — and for good reason. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that amplifies your body's own GH pulses rather than replacing them entirely, offering a more physiological approach to GH optimization than exogenous HGH.

This guide covers everything you need to know: the science behind how it works, the critical difference between the DAC and no-DAC variants, dosing protocols, benefits supported by research, the renowned CJC-1295 + Ipamorelin stack, and its legal and regulatory status in 2026.

What Is CJC-1295?

CJC-1295 is a 30-amino acid synthetic peptide designed to mimic endogenous GHRH — the hypothalamic hormone that signals the pituitary gland to release growth hormone. It was originally developed by ConjuChem Biotechnologies and studied in clinical trials for GH deficiency.

Natural GHRH has a very short half-life (roughly 7 minutes in circulation) due to rapid cleavage by the enzyme dipeptidyl peptidase-IV (DPP-IV). CJC-1295 addresses this through strategic amino acid substitutions that protect against enzymatic degradation, significantly extending its active duration.

The result is a peptide that binds to GHRH receptors on pituitary somatotroph cells, activates adenylate cyclase, increases intracellular cyclic AMP (cAMP), and triggers the synthesis and pulsatile release of growth hormone — all while working within the body's natural feedback systems.

DAC vs. No-DAC: The Critical Difference

The most important distinction in CJC-1295 is whether it contains a Drug Affinity Complex (DAC) — a reactive maleimido group that allows the peptide to covalently bind to albumin in the bloodstream.

CJC-1295 Without DAC (Modified GRF 1-29)

Without DAC, CJC-1295 has a half-life of approximately 30 minutes to 1 hour. It produces a discrete, pulsatile GH release pattern that closely mirrors the body's natural GH secretion rhythm. This version is sometimes called "Modified GRF 1-29" or "Mod GRF 1-29" in research communities.

Key characteristics:

• Half-life: ~30–60 minutes
• Produces clean, pulsatile GH spikes
• Requires daily or multiple-daily dosing
• Preserves natural GH rhythm — preferred for most protocols
• Ideal for stacking with GHRPs like Ipamorelin

CJC-1295 With DAC

The DAC version binds covalently to albumin once injected, which protects it from degradation and creates a slow-release depot in the bloodstream. This extends the half-life to approximately 6–8 days.

A landmark 2006 study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that a single injection of CJC-1295 with DAC elevated mean GH levels 2–10-fold for 6+ days and maintained elevated IGF-1 levels for up to 14 days.

Key characteristics:

• Half-life: ~6–8 days
• Produces sustained, blunted GH elevation rather than discrete pulses
• Requires only 1–2 injections per week
• Less physiological GH pattern; less commonly stacked with GHRPs
• May be preferred for convenience or specific therapeutic contexts

Bottom line: For most research and optimization protocols, the no-DAC variant is preferred because it preserves the pulsatile nature of GH secretion and stacks synergistically with GHRPs. The DAC version trades physiological fidelity for convenience.

Mechanism of Action

CJC-1295's mechanism operates through the hypothalamic-pituitary-somatotropic axis:

1. GHRH receptor binding: CJC-1295 binds to GHRH receptors (GHRHR) on anterior pituitary somatotrophs
2. cAMP cascade: Receptor activation stimulates adenylate cyclase, increasing intracellular cAMP
3. GH synthesis and release: Elevated cAMP drives both GH gene transcription and exocytosis of stored GH
4. IGF-1 production: Released GH travels to the liver and peripheral tissues, stimulating IGF-1 synthesis — the downstream anabolic mediator
5. Feedback preservation: Somatostatin feedback remains intact, preventing uncontrolled GH elevation

This feedback-intact mechanism is one of CJC-1295's most important safety features. Unlike exogenous HGH, which bypasses regulatory controls entirely, CJC-1295 works within the body's own homeostatic systems.

Benefits Supported by Research

Increased GH and IGF-1 Levels

This is the primary, well-documented effect. The 2006 ConjuChem trial showed 2–10x increases in mean GH levels and sustained IGF-1 elevation with the DAC variant. Multiple studies confirm the no-DAC variant produces significant GH pulses within 15–30 minutes of subcutaneous injection, with GH levels returning to baseline within 2–3 hours.

Body Composition: Fat Loss and Lean Mass

Elevated GH activates hormone-sensitive lipase, promoting lipolysis (breakdown of stored fat), particularly visceral adipose tissue. Concurrently, GH enhances protein synthesis through IGF-1-mediated activation of the mTOR and PI3K/Akt pathways.

A 2024 prospective observational study (n=48, aged 40–65, 12-month duration) examining CJC-1295/Ipamorelin in adults found results consistent with earlier research: approximately 10–15% reductions in visceral fat and modest lean mass gains over 6–12 months of use.

Recovery and Tissue Repair

GH and IGF-1 play central roles in tissue regeneration. Research demonstrates:

• Activation of satellite cells for muscle fiber repair
• Enhanced collagen synthesis for connective tissue and tendon repair
• Acceleration of wound healing and tissue remodeling
• Improved joint health through increased synovial fluid and cartilage repair signaling

Sleep Quality

Research dating to the 1990s has consistently shown that GHRH activity reduces wakefulness and increases slow-wave (deep) sleep — the phase most critical for physical recovery and memory consolidation. Many users report improved sleep quality within the first 2–3 weeks of use, often cited as one of the earliest and most noticeable effects.

Anti-Aging and Longevity

GH levels decline approximately 15% per decade after age 30 — a process called somatopause. This decline is associated with increased visceral fat, decreased lean mass, reduced bone density, impaired immune function, and cognitive changes. By stimulating more youthful GH secretion, CJC-1295 may partially offset these age-related changes.

Additional potential anti-aging effects include improved skin elasticity (through collagen stimulation), enhanced cognitive performance, and better metabolic flexibility.

Dosing Protocols

CJC-1295 No-DAC (Recommended for Most Protocols)

Standard dose: 100–300 mcg per injection
Frequency: Once daily (or 2–3x daily for more aggressive protocols)
Timing: Before bed on an empty stomach (to coincide with natural nocturnal GH pulse) or pre/post workout
Route: Subcutaneous injection
Cycle length: 8–16 weeks on, 4–8 weeks off

Titration approach:

• Week 1–2: 100 mcg/day
• Week 3–4: 150 mcg/day
• Week 5+: 200–300 mcg/day as tolerated

CJC-1295 With DAC

Standard dose: 1–2 mg per injection
Frequency: Once or twice weekly
Timing: Any time of day
Route: Subcutaneous injection
Cycle length: 8–12 weeks on, 4–8 weeks off

Important: Due to its ~8-day half-life, DAC takes approximately 3–4 weeks to reach steady-state levels. Do not escalate dose prematurely.

The CJC-1295 + Ipamorelin Stack: The Gold Standard

If CJC-1295 is the accelerator for GH release, Ipamorelin is the second pedal. This combination is widely considered the gold standard GHRH/GHRP stack in peptide research for good reason.

Why They Work Synergistically

CJC-1295 and Ipamorelin act through entirely different receptors and mechanisms:

• CJC-1295 acts on GHRH receptors, amplifying GH pulse amplitude
• Ipamorelin acts on ghrelin receptors (GHS-R1a), providing an independent GH-stimulating signal and suppressing somatostatin

When co-administered, these two mechanisms are additive — and often synergistic. Studies suggest the combined GH pulse can be 5–10x greater than either peptide alone. The dual mechanism also helps prevent receptor fatigue that can occur with single-agent protocols.

Ipamorelin is particularly valued as the GHRP pairing because, unlike GHRP-2 or GHRP-6, it does not significantly raise cortisol, prolactin, or stimulate hunger. For full details on Ipamorelin, see our Ipamorelin Complete 2026 Guide.

Stack Protocol (No-DAC CJC-1295 + Ipamorelin)

Dose: 100–300 mcg of each peptide per injection
Timing: Co-injected (same syringe or separate, same site) before bed and/or pre-workout
Frequency: 1–2x daily
Cycle: 12 weeks on, 4–6 weeks off

The most common approach is a single bedtime injection of 200 mcg CJC-1295 no-DAC + 200 mcg Ipamorelin, timed to align with and amplify the natural nocturnal GH surge.

Expected Timeline

• Weeks 1–3: Improved sleep quality, increased recovery speed, subtle energy improvements
• Weeks 4–6: Noticeable changes in body composition; improved muscle fullness, reduced water retention in some users
• Weeks 8–12: Measurable lean mass gains, significant fat loss (especially visceral), improved skin texture, strength improvements

Side Effect Profile

CJC-1295 is generally well-tolerated when used within recommended dose ranges. Reported side effects include:

• Water retention: Mild, temporary puffiness — most common in early weeks; typically resolves with dose adjustment
• Injection site reactions: Mild redness, swelling, or itching at the injection site
• Flushing: Transient facial or whole-body warmth, typically within minutes of injection
• Headache: Occasional; usually dose-dependent
• Tingling or numbness: Particularly in hands — similar to early carpal tunnel symptoms; suggests dose is too high
• Fatigue: Paradoxical fatigue occasionally reported, particularly at higher doses

More serious concerns with sustained high-dose use:

• Pituitary receptor desensitization: Continuous use without cycling can blunt pituitary responsiveness over time — cycling protocols (e.g., 12 weeks on / 4–6 weeks off) are important
• IGF-1 elevation: Chronically elevated IGF-1 has been theoretically associated with cancer promotion in susceptible individuals — monitoring IGF-1 levels is advisable with long-term use

CJC-1295 vs. Other GHRHs

CJC-1295 no-DAC is functionally equivalent to Modified GRF 1-29, and both are improvements over native GHRH 1-29 (sermorelin) due to greater stability. Sermorelin has a half-life of only ~10–12 minutes, making CJC-1295's ~30–60 minute window considerably more practical.

Compared to the DAC variant, no-DAC provides a more physiological pulsatile pattern. For users who want to preserve the natural rhythm of GH secretion — which matters for avoiding receptor desensitization and maintaining the anabolic/lipolytic balance — no-DAC is the preferred choice.

Reconstitution and Storage

CJC-1295 is supplied as a lyophilized (freeze-dried) powder:

• Reconstitution: Add bacteriostatic water (BW) slowly to the vial; do not shake — swirl gently
• Typical reconstitution: 2 mL BW per 2 mg vial → 1 mcg/µL (or adjust to your desired concentration)
• Storage before reconstitution: Refrigerated at 2–8°C; can be kept at room temperature for short periods if sealed
• Storage after reconstitution: Refrigerated at 2–8°C; use within 28–30 days
• Never freeze reconstituted peptide

Legal and Regulatory Status (2026)

CJC-1295 is not approved by the FDA for human therapeutic use. It is classified as a research chemical in the United States and most other jurisdictions. In 2024, the FDA took action to restrict the compounding of several peptides including CJC-1295 (both variants) and Ipamorelin, classifying them as "difficult to compound" substances and limiting their availability through 503A and 503B compounding pharmacies.

As of 2026, the regulatory landscape remains in flux. Some compounding pharmacies continue to operate in various states, and the legal status for personal research use is a gray area. Users should verify current regulations in their jurisdiction and consult with a qualified healthcare provider before beginning any peptide protocol.

CJC-1295 is also banned by WADA and most major sporting organizations as a prohibited performance-enhancing substance.

Frequently Asked Questions

Can I inject CJC-1295 and Ipamorelin in the same syringe?

Yes. Both peptides are compatible when mixed in the same syringe and co-injected. Many practitioners prefer this for convenience. Draw each into the syringe separately and inject immediately after preparation.

How soon will I see results?

Most users report improved sleep quality and recovery within 2–3 weeks. Meaningful body composition changes typically become apparent at 6–8 weeks, with more substantial results at the 10–12 week mark.

Do I need to fast before injecting?

For bedtime dosing, inject at least 2 hours after your last meal. Elevated insulin from food consumption can blunt the GH pulse. The same applies to pre-workout dosing — injecting in a fasted state maximizes the GH response.

What is the difference between CJC-1295 and sermorelin?

Both are GHRH analogs, but CJC-1295 (no-DAC) has a significantly longer half-life (~30–60 min vs. ~10–12 min for sermorelin) due to its amino acid modifications. Sermorelin has an FDA-approved use history (for pediatric GHD) and is sometimes available by prescription; CJC-1295 is research-only in the US.

Conclusion

CJC-1295 remains one of the most scientifically supported and practically effective peptides for growth hormone optimization. Whether your goals are body composition, recovery acceleration, sleep improvement, or anti-aging, its mechanism — amplifying your body's own GH pulsatility within intact feedback controls — makes it both effective and more physiologically appropriate than exogenous HGH.

The no-DAC variant, particularly when stacked with Ipamorelin, represents the gold standard approach: two distinct GH-stimulating mechanisms working synergistically to produce robust, clean GH pulses. With a sound dosing and cycling protocol, it's a highly effective tool in the peptide toolkit.

Always source from reputable, third-party-tested suppliers, work with a knowledgeable healthcare provider when possible, and stay current on the evolving regulatory landscape in your jurisdiction.